Upregulation of the p53 pathway may affect HSCs and transform HSCs into pre-leukemic stem cells with a significant risk of developing blood cancer, which would be concordant with the clinical results that AML1 has p53 mutations (Supplementary Table 1). This evidence concerns the gene TP53 and hematopoietic and lymphoid system neoplasm.